Applying Glycobiology To Develop Novel Medicines



IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP compounds are novel small molecule glycan therapeutics that inhibit selectin and complement activity. These compounds have the potential to (i) prevent immune response to AAV gene therapy and enabling AAV re-administration, (ii) rescue sickle cell disease patients in the prodromal phase of vasoocclusive crisis, (iii) treat other hematological diseases, such as hemolytic anemia, and (iv) inhibit cancer metastasis.


To pioneer the development of novel glyco-medicines


Our Team

Rinko Ghosh, MS, MBA


Jocelyn Jackson

Acting CFO

Peggy McLaughlin

VP of Clinical Operations

Gabriel Njikang, PhD
Director of CMC

John Paderi, PhD

Chief Science Officer

Kate Stuart, PhD

 VP of Program Management

Robert Van Gorp

VP of Strategic Sourcing

Board of Directors

Rinko Ghosh, MS, MBA

Vlad Hogenhuis, MD, MBA

John Paderi, PhD

Clinical and Scientific Advisors

Science Student


IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat diseases a broad spectrum of diseases, including those involving immune regulation and inflammatory processes.